drugset / Trial / NCT01512108

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

NCT01512108

Phase 3 Completed 363 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial was conducted in Japan. The aim of this trial was to evaluate the safety and efficacy of once daily administration of liraglutide in combination with an oral anti-diabetic drug (OAD) in Japanese subjects with type 2 diabetes who are insufficiently controlled on OAD monotherapy. All subjects will continue their pre-trial OAD (either glinide, metformin, alpha-glucosidase inhibitor or thiazolidinedione) during the trial at unchanged type and dose.

Timeline

Start
2012-01-10
Primary completion
2013-04-26
Completion
2013-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 0.9 mg Subcutaneous